Johnson & Johnson · JNJ · FY2025 Q3 · Calendar Q4 2025

J&J: Growth broadens as pipeline and MedTech priorities advance

The supplied analysis strengthens the case that diversified product growth, pipeline launches, and MedTech expansion can support J&J’s operating trajectory. That constructive view is tempered by persistent STELARA erosion, litigation, policy exposure, and execution risk around the orthopaedics separation and regulatory pipeline.

Why did JNJ fall 0.0% after beating EPS estimates in FY2025 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $617.01B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.80 Consensus $2.76
EPS surprise +1.4% Reported versus consensus
Reported revenue $23.99B Consensus $23.76B
Revenue surprise +1.0% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -0.0% Event window
SPY move -0.1% Same window
Abnormal move +0.1% Stock minus SPY
Volume 1.5× Versus trailing sessions
Subsequent drift +1.6% Up to 20 sessions
JNJSPY benchmark

Ask FN2 about JNJ FY2025 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, the current analysis adds a clearer emphasis on the orthopaedics separation, continued MedTech expansion, rising R&D and manufacturing investment, and a broader set of late-stage pipeline opportunities. Guidance sentiment remains raised, while the risk discussion now places more weight on separation execution, policy headwinds, and regulatory timing.

Guidance delta

Guidance sentiment remained raised: the current analysis says full-year operational sales guidance was raised to a $93.2 billion midpoint, following the prior quarter's guidance raise.

Key takeaways

  • Management described Q3 sales growth of 5.4% despite a 640-basis-point STELARA loss-of-exclusivity headwind.
  • DARZALEX, CARVYKTI, TREMFYA, and SPRAVATO were identified as major growth contributors, while MedTech and acquisitions broadened the portfolio.
  • The orthopaedics separation is intended to sharpen focus, but execution, margin, and capital-allocation questions remain.
  • The supplied analysis supports a constructive operating picture, not a risk-free outlook: STELARA pressure, litigation, policy, and regulatory timing are still material variables.

Management priorities

  • Advance high-growth Innovative Medicine launches and pipeline assets, including TREMFYA, Inlexo, and icotrokinda.
  • Expand cardiovascular, robotic-surgery, and vision MedTech platforms, including Shockwave and Ottava.
  • Continue R&D investment and U.S. manufacturing expansion.
  • Execute the orthopaedics separation while maintaining disciplined capital allocation.

Follow JNJ with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
JNJ REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $21B Q4 '23 actual $21B, beat Q1 '24 estimate $21B Q1 '24 actual $21B, match Q2 '24 estimate $22B Q2 '24 actual $22B, beat Q3 '24 estimate $22B Q3 '24 actual $22B, beat Q2 '25 estimate $23B Q2 '25 actual $24B, beat Q3 '25 estimate $24B Q3 '25 actual $24B, beat Q4 '25 estimate $24B Q4 '25 actual $25B, beat Q1 '26 estimate $24B Q1 '26 actual $24B, beat Q2 '26 estimate $25B Q2 '26 actual $25B, beat Q3 '26 estimate $25B Q3 '26 actual $25B, match Q4 '26 estimate $26B Q1 '27 estimate $26B
Show less

Analyst Consensus ?

ConsensusHold40 ratings
Bullish2152.5%
Neutral1640.0%
Bearish37.5%

Analyst 52W Price Targets

$270.47Current
$90Low
$230.82Average
$320High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 16, 2026
Morgan Stanley Overweight OverweightMaintainOct 15, 2026
RBC Capital Outperform OutperformMaintainOct 14, 2026
Leerink Partners Outperform OutperformMaintainOct 14, 2026
Guggenheim Buy BuyMaintainOct 7, 2026
Show 35 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $270.47. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Evercore ISIAnalyst unavailable$300$258.74 +10.9%Oct 20, 2026
Wells FargoLarry Biegelsen$287$253.28 +6.1%Oct 16, 2026
BernsteinLee Hambright$270$259.85 -0.2%Oct 15, 2026
RBC CapitalAnalyst unavailable$280$251.68 +3.5%Oct 14, 2026
Leerink PartnersAnalyst unavailable$272$251.75 +0.6%Oct 14, 2026
See 103 more

Track every rating change on JNJ the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Historical context

All JNJ earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the JNJ recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-03T18:10:44.784535+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-03T18:10:44.781776+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-03. For educational purposes only; not investment advice.